The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
DJ, Those ask prices of 1.40 and 1.80 you are seeing are unrealistic - just window dressing. Everything else points to buys IMO.
... surely significant?
66,666 !!
Surely significant. Belzeebub buying?
.... Wednesday was supposed to be a good day? Can't get good clairvoyants these days.
Well, if anyone genuinely knew something, they still couldn't tell you! No point asking.
Triflepig, Even IF liver toxicity is a substantive issue after further investigation (which IS needed to confirm or otherwise), lots of theraputics cause liver problems yet the risk/reward ratio keeps them on the market. AND, yes, all sorts of technology/biology changes could make Iclaprim valuable.
Mark, I understand. It's just that I wouldn't want people to be persuaded by the claims, not yours, that the future is necessarily the same as the past.
Not yet. Though they probably will one day, by phage I would imagine.
It's for 37000 shares. Peanuts.
B1ll, I'd reply but I genuinely don't know what you mean.
While I appreciate the time and effort that goes into the history lesson (by both posters) that is Iclaprim, I do feel the need to point out that the past is pretty irrelevant, especially in the world of biotech, where altered circumstances can turn things on a sixpence. Those looking to the past are like nineteenth century investors buying animal-fat candles, not believing that mineral oils are about to shake the world of heat and light. Or people in 2019 investing in retail properties. It's all about the future - that's what makes it a bit of a gamble.
I suspect they want it to be marketed. They just want to own it.
.. although give it 5 minutes and someone will pop up to claim it was a sell.
... late buy.
I, for one, have no explanation but it is something that has persuaded myself and some other LTHs that some organisation(s) see value here, even if it might be buried beneath a mass of skulduggery and shady dealings! I'm not usually a conspiracy theorist, but the way this share behaved after NASDAQ IPO (and not before) has been very strange, and I include the FDA decision in that package. So it's something that involves the USA, at least one organisation with market access and some robots to call on, and (of course) a wagonload of paid bashers. I'm not certain that points only one way, but I'm betting it might - remember the Buffet homily about patience - the big organisations are very, very good at it.... and we are not.
I'm investing in truffle-flavoured, non-steroid analgesics. Can't go wrong.
Perhaps because it was an 'indicative' sell but but not in fact a sell? Look at the trades either side...
Correct, and I think it's more accurate to say that the FDA simply want an understanding of any liver problems before they could approve - nothing else held them back. Because the liver is involved in detoxifying pretty much everything that enters your bloodstream, there are millions of things that 'excite' the liver and cause temporary changes in its biochemistry, but that doesn't mean they are long-term dangerous at the right doses. And, even with slight risk, the benefits may easily outweigh the costs. Best case scenario IMO is if someone sees value in a re-application for Iclaprim, not for skin infections, but for lung infections. The process could take a while (or, with the COVID situation, perhaps not too long) and, pending approval, I wouldn't be surprised if the SP bounced around the 20-30p mark, as it used to do back in the day (mind you, it's fluctuations were baffling even then...) As I say, best case ... but it would certainly explain the presence of the basher army .
.... might have been hard to fill. In which case tomorrow might be another day, as Proust once exclaimed.